CARMEL, Ind., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, MD, Chief Medical Officer, will participate in a fireside chat at the Stifel 2025 Virtual Cardiometabolic Forum on September 30. Stifel 2025 Virtual Cardiome ...

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday.Shares of Stitch Fix, Inc. (NASDAQ: SFIX) dipped 7.6% to $5.21 in pre-market trading following the release of fourth-quarter results.Stitch Fix reported quarterly losses of seven cents per share, which beat the consensus estimate for losses of 10 cents. Quarterly revenue came in at $311.22 million, which beat the Street estimate of $305.83 million.Stitch Fix shares fell 4.6% to $5.38 in pre-market trading.Here a ...

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday.Shares of Stitch Fix, Inc. (NASDAQ: SFIX) dipped 7.6% to $5.21 in pre-market trading following the release of fourth-quarter results.Stitch Fix reported quarterly losses of seven cents per share, which beat the consensus estimate for losses of 10 cents. Quarterly revenue came in at $311.22 million, which beat the Street estimate of $305.83 million.Stitch Fix shares fell 4.6% to $5.38 in pre-market trading.Here a ...

Meetings with Growth-Oriented Investors, September 26 to 28, 2025MISSISSAUGA, Ontario, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be presenting to investors at the Muskoka Capital Event, organized by Capital Event Management Ltd. and being hosted at the JW Marriott Rosseau Muskoka, in Minett, Ontario, September 26 to 28, 2025. Microbix’s CEO, Cameron Groome, and COO, Ken Hughes ...

PresentationIt is now my pleasure to turn the call over to MBX Biosciences Senior Director of Investor Relations and Communications, Jim DeNike.Ladies and gentlemen, greetings, and welcome to MBX Biosciences Conference Call. Today's call is being recorded. [Operator Instructions] As a reminder, this conference is being recorded.Jim DeNike Thanks, Rob. Good morning, and thank you for joining us this morning to review the exciting top line results from our Avail Phase II clinical trial. I'm very pleased to re ...

CARMEL, Ind., Sept. 24, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the pricing of its upsized public offering of 11,108,055 shares of its common stock at a price to the public of $18.00 per share. The gross proceeds to MBX Biosciences from the offering, before deducting underwriting discounts and co ...

Shares of MBX Biosciences, Inc. (MBX) have gained 44% over the past four weeks to close the last trading session at $20, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $37.71 indicates a potential upside of 88.6%.The mean estimate comprises seven short-term price targets with a standard deviation of $4.23. While the lowest estimate of $30.00 indicates a 50% increase from the cu ...

With U.S. stock futures trading slightly lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:Wall Street expects AutoZone Inc. AZO to report quarterly earnings at $50.83 per share on revenue of $6.24 million before the opening bell, according to data from Benzinga Pro. AutoZone shares slipped 0.5% to close at $4,121.00 on Monday.Firefly Aerospace Inc. FLY posted a second-quarter loss of $5.78 per share, versus a year-ago loss of $4.60 per share. Its sales decl ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?It has been a good day for companies involved in peptide drug design and development. News broke this morning that Metsera and its portfolio of glucagon like peptide 1 receptor agonist ("GLP-1 RA") drugs is set to ...

CARMEL, Ind., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed underwritten public offering of 10,000,000 shares of its common stock. Furthermore, MBX Biosciences ...